Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-02-11

FDA Approved: ESBRIET — Supplemental Application (Genentech, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for Esbriet (pirfenidone) from Genentech, resulting in labeling changes for the product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Esbriet (pirfenidone)

Snippet

SUPPL AP for ESBRIET (PIRFENIDONE)